Currently, we are conducting a clinical phase I study of siRNA targeting RPN2 in advanced breast cancer patients in Japan and anticipate that this study will generate novel information that will be useful for NSCLC treatment. Here, RPN2 is linked to non-small cell lung carcinoma.